In addition to augmenting antitumor immunity, LSD1 ablation can suppress the stem cell-like properties of HNSCC, HCC, glioma, small cell lung cancer, and breast cancers of luminal-B, HER2-positive, and TNBC subtypes through attenuating Wnt/β-catenin, Notch, BMI1, and SOX2-deriven stemness signaling. This evidence concerns the gene ERBB2 and breast carcinoma.